Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
16 February 2023 - 11:00PM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune
disease, today announced it will report its fourth quarter and
full year 2022 financial results and provide a general business
overview on Thursday, February 23, 2023.
Title: Shattuck Labs Fourth-Quarter and
Full-Year 2022 Earnings Conference CallSpeakers:
Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite,
CMODate & Time: Thursday, February 23, 2023 at
4:45 p.m. ETDial-in Details: Toll-Free Dial-In
Number: (888) 440-4368
Toll
Dial-In Number: (646) 960-0856
Conference ID:
5023003 Webcast
Details: https://events.q4inc.com/attendee/940317356
To listen to the live webcast, please visit the Investor
Relations page of the Shattuck Labs website here. Participants
may register for the call here. While not required, interested
participants are encouraged to join 10 minutes prior to the start
of the event.
A replay of the webcast will be available following the
conclusion of the live call and will be accessible on the Company’s
website.
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, ARC®, platform simultaneously
inhibit checkpoint molecules and activate costimulatory molecules
with a single therapeutic. The company’s lead SL-172154
(SIRPα-Fc-CD40L) program, which is designed to block the CD47
immune checkpoint and simultaneously agonize the CD40 pathway, is
being evaluated in multiple Phase 1 trials. Additionally, the
company is advancing a proprietary Gamma Delta T Cell Engager,
GADLEN™, platform, which is designed to bridge gamma delta T cells
to tumor antigens for the treatment of patients with cancer.
Shattuck has offices in both Austin, Texas and Durham, North
Carolina. For more information, please visit:
www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
Investor & Media Contact: Conor
RichardsonVice President of Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024